Get the Stockscreener App
1.64
2.50%
0.04
After Hours:
1.60
-0.04
-2.44%
Q 32 Bio Inc stock is traded at $1.64, with a volume of 517.78K.
It is up +2.50% in the last 24 hours and down -24.07% over the past month.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
See More
Previous Close:
$1.60
Open:
$1.59
24h Volume:
517.78K
Relative Volume:
2.28
Market Cap:
$20.00M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.09%
1M Performance:
-24.07%
6M Performance:
-96.34%
1Y Performance:
+0.00%
1-Day Range:
$1.5171
$1.7776
1-Week Range:
$1.40
$1.80
52-Week Range:
$1.40
$53.79
Q 32 Bio Inc Stock (QTTB) Company Profile
Name
Q 32 Bio Inc
Sector
Industry
Phone
781-999-0232
Address
830 WINTER STREET, WALTHAM
Compare QTTB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
1.64 | 20.00M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-11-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-11-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | Raymond James | Strong Buy |
| Sep-11-24 | Initiated | Wells Fargo | Overweight |
| Jun-17-24 | Initiated | Guggenheim | Buy |
| May-21-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-22-22 | Reiterated | BTIG Research | Neutral |
| Feb-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-22-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-02-21 | Initiated | Stifel | Hold |
| Dec-14-20 | Resumed | H.C. Wainwright | Buy |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-16-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-24-20 | Initiated | Chardan Capital Markets | Buy |
| Nov-01-19 | Initiated | Oppenheimer | Perform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
View All
Q 32 Bio Inc Stock (QTTB) Latest News
Layoff Tracker: Gilead, Sail, Carisma and More Slash Headcounts - BioSpace
Q32 Bio Inc. (NASDAQ:QTTB) Receives $24.71 Average Target Price from Brokerages - Defense World
QTTB stock touches 52-week low at $1.79 amid market challenges By Investing.com - Investing.com South Africa
QTTB stock touches 52-week low at $1.79 amid market challenges - Investing.com India
Fierce Biotech Layoff Tracker 2025: Elevation eliminates 70% of staff; Vaxart trims team - Fierce Biotech
Oppenheimer maintains Q32 Bio at Outperform, $20 target - Investing.com
Oppenheimer maintains Q32 Bio at Outperform, $20 target By Investing.com - Investing.com UK
Wells Fargo & Company Lowers Q32 Bio (NASDAQ:QTTB) Price Target to $15.00 - Defense World
Q32 Bio price target lowered to $15 from $16 at Wells Fargo - TipRanks
Q32 Bio Inc’s Intellectual Property Challenges: Navigating Risks and Competitive Pressures - TipRanks
Q32 Bio Reports Promising Trial Results and Financials - TipRanks
Q32 Bio: Q4 Earnings Snapshot - Midland Daily News
Q32 Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Q32 Bio Inc. SEC 10-K Report - TradingView
Q32 Bio: Q4 Earnings Snapshot -March 11, 2025 at 07:21 am EDT - MarketScreener
Q32 Bio's Breakthrough: Alopecia Drug Success Backed by $78M War Chest - StockTitan
Q32 Bio Inc. (NASDAQ:QTTB) Shares Purchased by Rhumbline Advisers - Defense World
Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart - TipRanks
Q32 Bio (QTTB) Projected to Post Earnings on Tuesday - Defense World
Can This New Alopecia Drug Maintain Hair Growth After Treatment Stops? Q32 Bio's Trial Reveals Surprising Results - StockTitan
Q32 Bio Inc. (NASDAQ:QTTB) Receives $24.86 Average PT from Brokerages - Defense World
Q32 Bio Inc expected to post a loss of $1.51 a shareEarnings Preview - TradingView
Reviewing Q32 Bio (NASDAQ:QTTB) & Ardelyx (NASDAQ:ARDX) - Defense World
Finance Watch: BridgeBio’s Oncology Spinout Reveals Go-Public Plan - Citeline News & Insights
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting - Longview News-Journal
Can This New Antibody Treatment Finally Solve Severe Alopecia Areata? AAD Meeting Will Reveal Key Data - Stock Titan
QTTB stock touches 52-week low at $2.27 amid market challenges - Investing.com Australia
QTTB stock touches 52-week low at $2.27 amid market challenges By Investing.com - Investing.com South Africa
Q32 Bio to Participate in Upcoming March Investor Conferences - PR Newswire
How Q32 Bio Plans to Showcase Its Immune Therapeutics Pipeline to Investors This March - Stock Titan
IPOs Numbers Rise In 2024 But Dwindling Returns Could Diminish Potential In 2025 - Citeline News & Insights
Savant Capital LLC Makes New $53,000 Investment in Q32 Bio Inc. (NASDAQ:QTTB) - Defense World
QTTB stock touches 52-week low at $2.44 amid market challenges - Investing.com India
Piper Sandler cuts Q32 Bio stock rating to neutral, slashes target - MSN
What is Leerink Partnrs’ Forecast for Q32 Bio Q1 Earnings? - Defense World
Petri Dish: a new AbbVie deal, layoffs, and CFO departures - The Business Journals
Bleakley Financial Group LLC Invests $149,000 in Q32 Bio Inc. (NASDAQ:QTTB) - Defense World
Q32 Bio refocuses on alopecia treatment, ends renal trial - MSN
BMO cuts Q32 Bio stock rating, slashes price target to $3 - MSN
BMO Capital Downgrades Q32 Bio (LSE:0T6G) - Nasdaq
Q32 Bio (NASDAQ:QTTB) Lowered to “Market Perform” Rating by BMO Capital Markets - Defense World
Q 32 Bio Inc Stock (QTTB) Financials Data
There is no financial data for Q 32 Bio Inc (QTTB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Q 32 Bio Inc Stock (QTTB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Violette Shelia M. | Chief Scientific Officer |
Oct 11 '24 |
Option Exercise |
3.12 |
4,574 |
14,271 |
17,874 |
| Violette Shelia M. | Chief Scientific Officer |
Oct 08 '24 |
Option Exercise |
3.12 |
13,300 |
41,496 |
13,300 |
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):